Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures.

PARP inhibitors